Pfizer Inc. (SNSE:PFE)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 130.48T +7.4% |
| Revenue (ttm) | 58.47T +1.4% |
| Net Income | 6.92T -5.0% |
| EPS | 1,212.17 -5.1% |
| Shares Out | n/a |
| PE Ratio | 18.86 |
| Forward PE | 8.86 |
| Dividend | 1,576.66 (5,865.55%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | n/a |
| Average Volume | 64 |
| Open | n/a |
| Previous Close | 26.88 |
| Day's Range | n/a |
| 52-Week Range | 22.18 - 27.80 |
| Beta | 0.71 |
| RSI | 59.34 |
| Earnings Date | May 5, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Mixed options sentiment in Pfizer with shares down 1.52%
Mixed options sentiment in Pfizer (PFE), with shares down 40c near $25.66. Options volume running well above average with 208k contracts traded and calls leading puts for a put/call ratio
Mixed options sentiment in Pfizer with shares up 0.28%
Mixed options sentiment in Pfizer (PFE), with shares up 8c, or 0.28%, near $26.52. Options volume roughly in line with average with 101k contracts traded and calls leading puts for
Pfizer sees high-single-digit annual revenue increases 2029-2033, WSJ reports
Pfizer (PFE) expects to return to consistent growth by 2029, targeting high-single-digit annual revenue increases through 2033, supported by a predictable post-patent portfolio transition and a pipeli...
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC
Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a “very c...
Pfizer CEO on AI-designed molecule, and race to use new tech
Pfizer CEO Albert Bourla says that company has reviewed its first AI-designed molecule. He says the company wants to be at the forefront of using artificial intellegence
BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports
BioNTech (BNTX) is closing multiple global sites and cutting up to 1,860 jobs while initiating up to $1B in share buybacks, as it shifts Covid-19 vaccine production to Pfizer (PFE)
3 Dividend Stocks for May 2026
This month's trio included a dividend aristocrat.
Pfizer Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong revenue and EPS growth, driven by robust performance in oncology, migraine, and vaccines. Legal settlements and pipeline progress support a high single-digit revenue CAGR post-2028, with disciplined capital allocation and cost management.
Pfizer Posts Better-Than-Expected Revenue, Profit
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook
Pfizer’s ($PFE) shares rose over 2% early Tuesday after the American pharma giant released first-quarter 2026 earnings results that surpassed the Wall Street consensus. This comes even as Pfizer maint...
Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.
Options Volatility and Implied Earnings Moves Today, May 05, 2026
Today, several major companies are expected to report earnings: Advanced Micro Devices (AMD), Energy Transfer (ET), Strategy (MSTR), Occidental Petroleum (OXY), Pfizer (PFE), Super Micro Computer (SMC...
Why selling these 3 dividend stocks could be a mistake
Investors are uncomfortable seeing losses, especially in stocks they rely on for steady income. Enterprise Products Partners (NYSE: EPD), Pfizer (NYSE: PFE) and UPS (NYSE: UPS) all fit that uneasy pro...
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
Pfizer posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched and acquired products showed growth. The pharmaceutical giant is looking to...
Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
Pfizer on Tuesday reported first-quarter profit above Wall Street estimates, boosted by sustained demand for older drugs such as blood thinner Eliquis.
Pfizer reports Q1 adjusted EPS 75c, consensus 72c
Reports Q1 revenue $14.5B, consensus $13.8B. Dr. Albert Bourla, Chairman and CEO of Pfizer (PFE): “We’re off to a strong start in 2026, and it reinforces our confidence that we
Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.96
Backs FY26 revenue view $59.5B-$62.5B, consensus $61.37B.
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bou...
Options Volatility and Implied Earnings Moves This Week, May 04 – May 07, 2026
This week, several major companies will be reporting earnings. Among them are Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Walt Disney (DIS), PayPal Holdings (PYPL), Pfizer (PFE). Ahead...
Pfizer Reports Q1 Earnings Tomorrow. What Shareholders Should Expect.
Pharmaceuticals giant Pfizer ($PFE) is set to report its Q1 earnings on May 5. The stock is up over 7% in the year-to-date as investors get excited about its drug
Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC
Arvinas (ARVN) with its partner Pfizer (PFE), announced that the U.S. Food and Drug Administration has granted approval for VEPPANU for the treatment of adults with estrogen receptor-positive/human ep...
US FDA approves Pfizer, Arvinas' breast cancer drug
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' drug for a type of breast cancer.
Pfizer's blood cancer drug meets main goal in late-stage trial
Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment in patients who received at least one prior line of treatment.